Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results From the Phase 3 PREVAIL Trial SAN FRANCISCO, CA -- (Marketwired) -- 01/28/14 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss the final results from the Phase 3 PREVAIL trial on January 30, 2014 at 1:30 pm Pacific Time. Dr. Tomasz M. Beer, M.D., F.A.C.P., professor of medicine and deputy director of the Knight Cancer Institute at Oregon Health & Science University, and co-principal investigator of the PREVAIL study will participate in the call. Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting: http://investors.medivation.com/events.cfm. About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com. Contacts: Patrick Machado Chief Business & Financial Officer (415) 829-4101 Anne Bowdidge Sr. Director, Investor Relations (650) 218-6900
Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results From the Phase 3 PREVAIL Trial
Press spacebar to pause and continue. Press esc to stop.